| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 05/25/2023 | Passage BIO, Inc. | PASG | Grant | Director Stock Option (Right to Buy) | 24k | $1.00 | $24k | | 05/25/2023 |
| 06/23/2022 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 15k | $1.34 | $20.1k | | 06/23/2022 |
| 06/17/2022 | Tempest Therapeutics, Inc. | OVAS | Grant | Stock Option (Right to Buy) | 3.5k | $2.08 | $7.3k | | 06/17/2022 |
| 05/26/2022 | Passage BIO, Inc. | PASG | Grant | Director Stock Option (Right to Buy) | 24k | $1.76 | $42.2k | | 05/26/2022 |
| 04/29/2022 | Tempest Therapeutics, Inc. | OVAS | Purchase | Common Stock | 2.1M | $2.36 | $5M | See Footnote | 04/29/2022 |
| 08/25/2021 | Gritstone bio, Inc. | GRTS | Other (acquisition) | Common Stock | 128 | $0.00 | $0 | | 08/25/2021 |
| 08/25/2021 | Gritstone bio, Inc. | GRTS | Other (disposition) | Common Stock | 6.7k | $0.00 | $0 | See Footnote | 08/25/2021 |
| 08/25/2021 | Gritstone bio, Inc. | GRTS | Other (acquisition) | Common Stock | 6.6k | $0.00 | $0 | See Footnote | 08/25/2021 |
| 08/25/2021 | Gritstone bio, Inc. | GRTS | Other (disposition) | Common Stock | 6.6k | $0.00 | $0 | See Footnote | 08/25/2021 |
| 08/25/2021 | Gritstone bio, Inc. | GRTS | Other (disposition) | Common Stock | 444.7k | $0.00 | $0 | See Footnote | 08/25/2021 |
| 08/25/2021 | Gritstone bio, Inc. | GRTS | Other (acquisition) | Common Stock | 6.7k | $0.00 | $0 | See Footnote | 08/25/2021 |
| 07/01/2021 | Tempest Therapeutics, Inc. | OVAS | Grant | Stock Option (Right to Buy) | 6.6k | $11.07 | $73.4k | | 07/01/2021 |
| 06/25/2021 | Tempest Therapeutics, Inc. | OVAS | Grant | Common Stock | 997.9k | $0.00 | $0 | By Versant Venture Capital VI, L.P. | 06/25/2021 |
| 06/25/2021 | Tempest Therapeutics, Inc. | OVAS | Grant | Common Stock | 1.2M | $0.00 | $0 | By Versant Venture Capital IV, L.P. | 06/25/2021 |
| 06/25/2021 | Tempest Therapeutics, Inc. | OVAS | Grant | Common Stock | 7.4k | $0.00 | $0 | By Versant Side Fund IV, L.P. | 06/25/2021 |
| 06/17/2021 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 15k | $26.58 | $398.7k | | 06/17/2021 |
| 06/11/2021 | Aligos Therapeutics, Inc. | ALGS | Other (acquisition) | Common Stock | 2.2k | $0.00 | $0 | | 06/11/2021 |
| 06/11/2021 | Aligos Therapeutics, Inc. | ALGS | Other (disposition) | Common Stock | 8.4k | $0.00 | $0 | See Footnote | 06/11/2021 |
| 06/11/2021 | Aligos Therapeutics, Inc. | ALGS | Other (acquisition) | Common Stock | 8.4k | $0.00 | $0 | See Footnote | 06/11/2021 |
| 06/11/2021 | Aligos Therapeutics, Inc. | ALGS | Other (disposition) | Common Stock | 9.7k | $0.00 | $0 | See Footnote | 06/11/2021 |
| 06/11/2021 | Aligos Therapeutics, Inc. | ALGS | Other (acquisition) | Common Stock | 9.7k | $0.00 | $0 | See Footnote | 06/11/2021 |
| 06/11/2021 | Aligos Therapeutics, Inc. | ALGS | Other (disposition) | Common Stock | 486k | $0.00 | $0 | See Footnote | 06/11/2021 |
| 05/27/2021 | Passage BIO, Inc. | PASG | Grant | Director Stock Option (Right to Buy) | 16.9k | $13.83 | $234k | | 05/27/2021 |
| 05/12/2021 | Adverum Biotechnologies, Inc. | ADVM | Grant | Stock Option (Right to Buy) | 40k | $3.70 | $148k | | 05/12/2021 |
| 04/26/2021 | Aligos Therapeutics, Inc. | ALGS | Other (disposition) | Common Stock | 486k | $0.00 | $0 | See Footnote | 04/26/2021 |
| 04/26/2021 | Aligos Therapeutics, Inc. | ALGS | Other (acquisition) | Common Stock | 9.7k | $0.00 | $0 | See Footnote | 04/26/2021 |
| 04/26/2021 | Aligos Therapeutics, Inc. | ALGS | Other (disposition) | Common Stock | 9.7k | $0.00 | $0 | See Footnote | 04/26/2021 |
| 04/26/2021 | Aligos Therapeutics, Inc. | ALGS | Other (acquisition) | Common Stock | 8.4k | $0.00 | $0 | See Footnote | 04/26/2021 |
| 04/26/2021 | Aligos Therapeutics, Inc. | ALGS | Other (disposition) | Common Stock | 8.4k | $0.00 | $0 | See Footnote | 04/26/2021 |
| 04/26/2021 | Aligos Therapeutics, Inc. | ALGS | Other (acquisition) | Common Stock | 2.2k | $0.00 | $0 | | 04/26/2021 |
| 12/30/2020 | Gritstone bio, Inc. | GRTS | Purchase | Common Stock | 1.3M | $3.71 | $5M | See Footnote | 12/30/2020 |
| 12/14/2020 | Adverum Biotechnologies, Inc. | ADVM | Other (acquisition) | Common Stock | 12.8k | $0.00 | $0 | | 12/14/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 2.1M | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 198.8k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 85.1k | $0.00 | $0 | See footnote | 10/20/2020 |
|